tomeko

Autosomal dominant hyperinsulinism due to Kir6.2 deficiency

Just diagnosed with Autosomal dominant hyperinsulinism due to Kir6.2 deficiency?

You are not alone. Here is where to start: learn the basics, find a specialist or center that sees Autosomal dominant hyperinsulinism due to Kir6.2 deficiency, look for clinical trials, and connect with others living with it — all in one place.

Open the full Autosomal dominant hyperinsulinism due to Kir6.2 deficiency hub →

Overview

Autosomal dominant hyperinsulinism due to Kir6.2 deficiency is a rare condition. Also known as Dominant KATP hyperinsulinism due to Kir6.2 deficiency, Autosomal dominant hyperinsulinemic hypoglycemia due to Kir6.2 deficiency. Tomeko brings together the specialists, research, clinical trials, treatments and community for Autosomal dominant hyperinsulinism due to Kir6.2 deficiency so you can go from overwhelmed to oriented. For authoritative medical detail, see the reference sources below.

Identifiers: ORPHA:276580 · OMIM 601820 · ICD-10 E16.1 · GARD 0017284

Find care for Autosomal dominant hyperinsulinism due to Kir6.2 deficiency

Authoritative references for Autosomal dominant hyperinsulinism due to Kir6.2 deficiency

Common questions

I was just diagnosed with Autosomal dominant hyperinsulinism due to Kir6.2 deficiency — what should I do first?

Start by learning the basics from an authoritative source, find a specialist or center that sees Autosomal dominant hyperinsulinism due to Kir6.2 deficiency, and connect with a patient organization. Tomeko brings these together on one hub.

Where can I find a specialist for Autosomal dominant hyperinsulinism due to Kir6.2 deficiency?

Use Tomeko's specialist and Centers-of-Excellence directories to find clinicians who treat Autosomal dominant hyperinsulinism due to Kir6.2 deficiency, filtered to your area.

Are there clinical trials for Autosomal dominant hyperinsulinism due to Kir6.2 deficiency?

Tomeko shows live, recruiting studies for Autosomal dominant hyperinsulinism due to Kir6.2 deficiency from ClinicalTrials.gov on the hub.

Informational only — not medical advice. Always consult a qualified clinician. Provider and reference data from public sources (NIH GARD, Orphanet, OMIM, HPO, MONDO, ClinicalTrials.gov, CMS NPPES). © Tomeko · tomekohealth.com